Royalty Pharma plc (RPRX) reports Q3 results; Offers Guidance
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $55.35 +3.32%
Financial Fact:
Loss per share - basic and diluted:: -0.17
Today's EPS Names:
CBRS, MAYS, CRMT, More
Financial Fact:
Loss per share - basic and diluted:: -0.17
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q3 resutls. Revenue for the quarter came in at $573 million versus the consensus estimate of $584.92 million.
GUIDANCE:
Adjusted Cash Receipts expected to be $2,750 to $2,800 million, which includes $458m from the acceleration of payments related to Pfizer’s acquisition of Biohaven.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
